What Laboratorios Beta does

Laboratorios Beta S.A. is a privately-held Argentine pharmaceutical manufacturer and marketer headquartered in Buenos Aires (Av. San Juan 2266, CABA), with a manufacturing plant located in La Rioja Province. The company commercializes more than 100 pharmaceutical products across nine therapeutic lines: Analgesic/Anti-inflammatory, Cardiology, Diabetology, Endocrinology/Metabolic, Gastroenterology, Gynecology, Neuropsychiatry, Rheumatology, and Urology, with a stated leadership position in the anti-inflammatory and anti-rheumatic segment of the Argentine market.

The product portfolio is built around branded generics and reformulated molecules rather than novel chemical entities, with notable franchises including the OXA line (multiple diclofenac presentations: oral, injectable, topical gel, soft capsules, combinations with paracetamol/codeine/vitamin B12), the MECANYL line (glucosamine/chondroitin-based rheumatologicals), the OXA anti-inflammatory line, the SIFEL/GLICINAL/ETACRIL diabetology franchise (sitagliptin, dapagliflozin, empagliflozin), and neuropsychiatry treatments such as PSICOASTEN, CLONAX, and DOMINIUM. The company's stated differentiator is its focus on innovative drug delivery systems and novel pharmaceutical forms (transdermal gels, soft capsules, controlled-release formulations) rather than active-ingredient invention.

The business operates a traditional domestic pharma distribution model, selling through pharmacy and medical channels in Argentina, with all prescription products compliant with ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) guidelines. The firm employs 501–1,000 people, has no disclosed revenue or funding history, and shows no signs of public listing, parent company, or institutional ownership.

Name

Laboratorios Beta

Legal name

Laboratorios Beta S.A.

Website

https://laboratoriosbeta.com.ar

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Laboratorios Beta S.A. is a privately-held Argentine pharmaceutical company that manufactures and markets over 100 branded generic drugs across nine therapeutic lines, with a leading position in anti-inflammatory and anti-rheumatic medications and a focus on innovative drug delivery formats.

Ownership category

akta.pro rank

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Laboratorios Beta is an Argentine pharmaceutical laboratory that manufactures and commercializes more than 100 pharmaceutical products across multiple therapeutic lines, with a recognized leadership position in anti-inflammatory and anti-rheumatic medications. The portfolio spans analgesics/anti-inflammatories, cardiology, diabetology, endocrinology/metabolism, gastroenterology, gynecology, neuropsychiatry, rheumatology, and urology, distributed through the pharmacy and medical channel in Argentina.

Product overview

Laboratorios Beta is an Argentine pharmaceutical company commercializing over 100 pharmaceutical products across 10 therapeutic lines: Analgesic/Anti-inflammatory, Cardiology, Diabetology, Endocrinology/Metabolic, Gastroenterology, Gynecology, Neuropsychiatry, Rheumatology, and Urology. The company operates in Buenos Aires with a manufacturing plant in La Rioja province. Notable product families include: OXA line (diclofenac-based anti-inflammatories in injectable, oral, and topical formulations), PSICOASTEN/CLONAX/LAGOTRAN/DROPICINE (CNS medications), SIFEL/GLICINAL/ETACRIL (diabetes treatments), ATEROCLAR/ATERONOVA (statins), ANDROLONE/DOXATEN (urologicals), FEMPRO/FEMTERONA (gynecologicals), ULTREX/PANGEST (gastrointestinals), and MECANYL/INMUNOARTRO (rheumatologicals). The company is recognized as a major producer of anti-inflammatory and anti-rheumatic medications with innovative drug delivery systems.

Differentiator

Problem solved

Functional benefit

Products and services

• OXA diclofenac anti-inflammatory line (OXAGESIC, OXA 50, OXA 75, OXA B12, OXA FORTE, OXA GEL, OXADISTEN, OXAPROST 75, OXAGESIC CB, OXAGESIC FORTE, OXA B12 I.M., OXA GEL PLUS, OXADISTEN CB, OXADISTEN Crema)

Segments8 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Laboratorios Roemmers: One of the largest Argentine pharmaceutical manufacturers with a similarly broad multi-therapeutic portfolio and own manufacturing. Most directly comparable peer given shared domestic market, similar breadth across therapeutic areas, and overlapping generic-and-branded positioning.
• Laboratorios Bagó: Major Argentine pharmaceutical group with own manufacturing, broad product lines, and presence in multiple LatAm markets. Direct competitor in generic and branded generics across overlapping therapeutic areas including NSAIDs, GI, and CNS.
• Laboratorios Gador: Argentine pharmaceutical laboratory with branded generic and innovative drug portfolio across multiple therapeutic lines. Closely comparable given shared domestic footprint, similar scale, and ANMAT-regulated branded-generic model.
• Laboratorios Montpellier: Argentine pharma with broad therapeutic portfolio and own manufacturing. Direct competitor in rheumatology, diabetology, CNS, and gynecology segments — categories overlapping with Laboratorios Beta's core lines.
• Laboratorios Richmond: Argentine pharmaceutical company with diversified therapeutic portfolio and domestic manufacturing capacity. Comparable in scale and product breadth, competing across similar therapeutic categories in the local market.
• Temis Lostaló: Argentine pharmaceutical laboratory focused on women's health and other therapeutic areas. Comparable given overlapping gynecological portfolio (e.g., Fempro, Femterona-style products) and Argentine-market presence.

Regional players

• Eurofarma: Brazilian pharmaceutical company with broad branded generics and innovative portfolio across LatAm. Comparable in therapeutic breadth and manufacturing-driven model, but operates primarily in Brazil and surrounding markets rather than competing head-to-head in Argentina.
• Genomma Lab: Mexican-headquartered LatAm pharma with branded generics and OTC portfolio across multiple countries. Comparable business model (branded generics, multi-therapeutic) but geographically distinct, with limited Argentina overlap.
• Asofarma: Mexican pharmaceutical company with broad branded generics portfolio across multiple therapeutic areas. Comparable in product breadth and therapeutic diversity, but primarily serves Mexico and select LatAm markets rather than Argentina directly.

Broad incumbents

• Sanofi Argentina: Argentine subsidiary of global pharma major with established presence across diabetes, CNS, and other therapeutic areas. Competes with Laboratorios Beta in several of Beta's growth segments (e.g., sitagliptin/diabetes) but as part of a much broader global portfolio rather than as a domestic specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Beta